Travel

[키워드] acute respiratory distress acute respiratory distress syndrome administration alveolar fluid clearance animal model animal models antimicrobial ARDS ASC benefit breath capital city Cell China Clinical studies clinical study Clinical use Comorbidity coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 outbreak COVID-19 patient Critical demonstrated distress edema effective Ex vivo Fever global pandemic globe greater Health Organization healthcare high mortality rate hospital resources human clinical trials human lung hypoxia illness immune response immune responses immunomodulatory activities in some in vivo Inflammation inhibit intravenous Intravenous administration intravenous route lead Local lung lung damage Lungs majority Mesenchymal stem cells molecules morbidity morbidity and mortality MSC MSCs multi-organ failure Multiple Novel coronavirus older patients Pain Patient patient mortality per day Pneumonia pulmonary disease Pulmonary edema Pulmonary function rationale reduce reduced respiratory respiratory distress respiratory symptoms risk Safe SARS-CoV-2 SARS-COV-2 infection severe disease Severe respiratory distress stem cell stem cells syndrome therapeutic option therapy Travel Treatment treatment of COVID-19 Viral viral outbreak viral respiratory with COVID-19 World Health Organization Wuhan
[DOI] 10.1186/s12967-020-02380-2 PMC 바로가기 [Article Type] Review